Patents by Inventor Gudula Riemen
Gudula Riemen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8192990Abstract: A method for introducing biologically active molecules into animal or human cells using an electric current includes suspending the cells and dissolving the biologically active molecules in a buffer solution including HEPES and at least 10 mmol×1?1 magnesium ions (Mg2+), the buffer solution having a buffer capacity of at least 20 mmol×1?1 ×pH?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C., and an ionic strength of at least 200 mmol×1?1. An electric voltage is applied to the suspension.Type: GrantFiled: January 19, 2011Date of Patent: June 5, 2012Assignee: Lonza Cologne GmbHInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Mueller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterhus, Michael Nix
-
Patent number: 8173416Abstract: The invention relates to a novel circuit arrangement for electrotransfection or electrofusion, which enables the transportation of DNA and/or other biologically active molecules to the nucleus of higher eukaryotic cells or the fusion of cells, independent of cell division and with reduced cell mortality.Type: GrantFiled: April 23, 2002Date of Patent: May 8, 2012Assignee: Lonza Cologne GmbHInventors: Herbert Müller-Hartmann, Gudula Riemen, Kirsten Rothmann-Cosic, Corinna Thiel, Ludger Altrogge, Meike Weigel, Rainer Christine, Elke Lorbach, Juliana Helfrich, Heike Wessendorf, Gregor Siebenkotten
-
Patent number: 8039259Abstract: A buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce the biologically active molecules into the cells using electric current. The buffer solution includes at least one of sodium succinate, mannitol and sodium lactobionate. The buffer solution has a buffer capacity of at least 20 mmol*l?1*pH?1 at a change in the from pH 7 to pH 8 and at a temperature of 25° C., and an ionic strength of at least 200 mmol * l?1.Type: GrantFiled: October 31, 2007Date of Patent: October 18, 2011Assignee: Lonza Cologne GmbHInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Mueller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterhus, Michael Nix
-
Patent number: 8003389Abstract: A method for introducing biologically active molecules into animal or human cells using electric current includes suspending the cells and dissolving the biologically active molecules in a buffer solution which has a buffer capacity of at least 20 mmol×l?1×pH?1 and an ionic strength of at least 200 mmol×l?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C. to form a suspension. The method further includes applying an electric voltage to the suspension so as to introduce the biologically active molecules into animal or human cells.Type: GrantFiled: November 9, 2006Date of Patent: August 23, 2011Assignee: Lonza Cologne GmbHInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Mueller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterhus, Michael Nix
-
Patent number: 7999073Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: GrantFiled: November 21, 2007Date of Patent: August 16, 2011Assignee: Lonza Cologne GmbHInventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Grabek, Andrea Mueller-Hartmann
-
Publication number: 20110117654Abstract: A method for introducing biologically active molecules into animal or human cells using an electric current includes suspending the cells and dissolving the biologically active molecules in a buffer solution including HEPES and at least 10 mmol×1?1 magnesium ions (Mg2+), the buffer solution having a buffer capacity of at least 20 mmol×1?1×pH?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C., and an ionic strength of at least 200 mmol×1?1. An electric voltage is applied to the suspension.Type: ApplicationFiled: January 19, 2011Publication date: May 19, 2011Applicant: LONZA COLOGNE AGInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Mueller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterhaus, Michael Nix
-
Patent number: 7704727Abstract: Disclosed is a device for processing biological material which at least comprises a chamber at least closable to the outside and having an inner space for receiving the biological material. The chamber comprises at least one electrode placed in contact with the inner space for generating an electric field. Also disclosed is a method for processing biological material. The biological material is introduced into the inner space above and the electrode can generate an electric field after said biological material is introduced by applying voltage to said electrode and a further electrode in contact with the inner space. The chamber comprises at least one inlet line having at least one opening arranged close to the electrode. The biological material is almost completely rinsed out of the inner space after the electric field is generated, via a solution guided via an inlet line of the chamber along at least one electrode.Type: GrantFiled: September 12, 2003Date of Patent: April 27, 2010Assignee: Lonza Cologne AGInventors: Gregor Siebenkotten, Herbert Müller-Hartmann, Gudula Riemen, Günter Kraus
-
Publication number: 20090023131Abstract: The invention relates to a novel circuit arrangement for electrotransfection or electrofusion, which enables the transportation of DNA and/or other biologically active molecules to the nucleus of higher eukaryotic cells or the fusion of cells, independent of cell division and with reduced cell mortality.Type: ApplicationFiled: August 9, 2007Publication date: January 22, 2009Applicant: AMAXA GMBHInventors: Herbert Muller-Hartmann, Gudula Riemen, Kirsten Rothmann-Cosic, Corinna Thiel, Ludger Altrogge, Meike Weigel, Rainer Christine, Elke Lorbach, Juliana Helfrich, Heike Wessendorf, Gregor Siebenkotten
-
Publication number: 20080220527Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: ApplicationFiled: November 21, 2007Publication date: September 11, 2008Applicant: AMAXA AGInventors: Hanns-Martin SCHMIDT, Ludger ALTROGGE, Dietmar LENZ, Gudula RIEMEN, Helmut BROSTERHUS, Elke LORBACH, Juliana HELFRICH, Katharina HEIN, Marion GREMSE, Tatjana MALES, Rainer CHRISTINE, Gregor SIEBENKOTTEN, Bodo ORTMANN, Tamara GRABECK, Andrea MULLER-HARTMANN
-
Publication number: 20080145938Abstract: A buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce the biologically active molecules into the cells using electric current. The buffer solution includes HEPES and at least 10 mmol*1?1 magnesium ions (Mg2+). The buffer solution has a buffer capacity of at least 20 mmol*1?1*pH?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C. The buffer solution also has an ionic strength of at least 200 mmol*1?1.Type: ApplicationFiled: October 31, 2007Publication date: June 19, 2008Applicant: AMAXA AGInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Muller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterbus, Michael Nix
-
Publication number: 20080113436Abstract: A buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using electric current. The buffer solution includes at least one of sodium succinate, mannitol and sodium lactobionate. The buffer solution has a buffer capacity of at least 20 mmol*l?1*pH?1 at a change in the pH from pH 7 to pH 8 and at a temperature of 25° C., and an ionic strength of at least 200 mmol*l?1.Type: ApplicationFiled: October 31, 2007Publication date: May 15, 2008Applicant: amaxa AGInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Muller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterbus, Michael Nix
-
Patent number: 7332332Abstract: The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce biologically active molecules into cells using an electric current. The inventive buffer solution has a buffering capacity of at least 20 mmol?1×pH?1 and an ionic strength of at least 200 mmol×1?1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25° C. The use of a buffer solution of this type allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in the buffer solution.Type: GrantFiled: April 23, 2002Date of Patent: February 19, 2008Assignee: Amaxa AGInventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Müller-Hartmann, Kirsten Rothmann, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterbus, Michael Nix
-
Patent number: 7320859Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: GrantFiled: January 10, 2002Date of Patent: January 22, 2008Assignee: Amaxa AGInventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tatjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Tamara Turbanski, Andreas Klaes
-
Publication number: 20070110736Abstract: The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an electric current and a buffer solution. The inventive buffer solution has a buffering capacity of at least 20 mmol*I?1*pH?1 and an ionic strength of at least 200 mmol* I?1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25 ° C. The use of a buffer solution of this type in the corresponding method allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in said buffer solution.Type: ApplicationFiled: November 9, 2006Publication date: May 17, 2007Inventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Muller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterhus, Michael Nix
-
Publication number: 20060160221Abstract: The invention relates to a device for processing biological material, which at least comprises a chamber which at least can be closed in relation to the outside and which comprises an inner space for receiving said biological material, wherein said chamber comprises at least one electrode which is placed in contact with said inner space of said chamber and is provided for generating an electric field. The invention also relates to a method for processing biological material, wherein said biological material is introduced into the inner space of a chamber which at least can be closed in relation to the outside and which comprises at least one electrode which is placed in contact with said inner space of said chamber and is provided for generating an electric field which is generated in said inner space after introducing said biological material by applying voltage to said electrode and a further electrode which is in contact with said inner space of said chamber.Type: ApplicationFiled: September 12, 2003Publication date: July 20, 2006Inventors: Gregor Siebenkotten, Herbert Muller-Hartmann, Gudula Riemen, Gunter Kraus
-
Publication number: 20050064596Abstract: The invention relates to a buffer solution for suspending animal or human cells and for dissolving biologically active molecules in order to introduce said biologically active molecules into the cells using an electric current and to a method for introducing biologically active molecules into animal or human cells using an electric current and a buffer solution. The inventive buffer solution has a buffering capacity of at least 20 mmol*I?1*pH?1 and an ionic strength of at least 200 mmol*I?1 during a change to the pH value from pH 7 to pH 8 and at a temperature of 25° C. The use of a buffer solution of this type in the corresponding method allows biologically active molecules to be introduced into animal and human cells with a high degree of transfection efficiency and at the same time a low cell mortality. Different cell types, in particular dormant and actively dividing cells of low activity, can be successfully transfected in said buffer solution.Type: ApplicationFiled: April 23, 2002Publication date: March 24, 2005Inventors: Gudula Riemen, Elke Lorbach, Juliana Helfrich, Gregor Siebenkotten, Herbert Muller-Hartmann, Kirsten Rothmann-Cosic, Corinna Thiel, Meike Weigel, Heike Wessendorf, Helmut Brosterbus, Michael Nix
-
Publication number: 20040137622Abstract: The present invention relates to a method for transfection of cells using at least one protein capable of forming nucleoprotein filaments, wherein the protein is initially modified with at least one functional component which influences one or more steps of the transfection, the nucleic acid to be transfected is then loaded with the modified protein, whereby the nucleic acid and the protein form a filament-like complex, and this complex is finally added to the cells to be transfected. The invention further relates to a transfection agent consisting of nucleoprotein filaments (NPF), with at least one nucleoprotein filament-forming protein being modified with at least one functional component for the transfection. Furthermore, the present invention relates to the use of the transfection agent according to the invention for producing a drug for gene therapeutic treatment of humans and animals.Type: ApplicationFiled: August 13, 2003Publication date: July 15, 2004Inventors: Hanns-Martin Schmidt, Ludger Altrogge, Dietmar Lenz, Gudula Riemen, Helmut Brosterhus, Elke Lorbach, Juliana Helfrich, Katharina Hein, Marion Gremse, Tarjana Males, Rainer Christine, Gregor Siebenkotten, Bodo Ortmann, Andrea Klacs
-
Publication number: 20040137603Abstract: The invention relates to a novel circuit arrangement for electrotransfection or electrofusion, which enables the transportation of DNA and/or other biologically active molecules to the nucleus of higher eukaryotic cells or the fusion of cells, independent of cell division and with reduced cell mortality.Type: ApplicationFiled: March 15, 2004Publication date: July 15, 2004Inventors: Herbert Muller-Hartmann, Gudula Riemen, Kirsten Rothmann-Cosic, Corinna Thiel, Ludger Altrogge, Meike Weigel, Rainer Christine, Elke Lorbach, Juliana Helfrich, Heike Wessendorf, Gregor Siebenkotten
-
Publication number: 20040014220Abstract: The invention relates to a novel method allowing the transport of DNA and/or other biologically active molecules into the nucleus of eukaryotic cells using electrical current, independently from cell division and with low cell mortality.Type: ApplicationFiled: July 18, 2003Publication date: January 22, 2004Inventors: Gregor Siebenkotten, Rainer Christine, Ludger Altrogge, Marion Gremse, Dietmar Lenz, Sabine Poppenborg, Gudula Riemen, Kirsten Rothmann, Corinna Thiel